Moderna and Merck announce ‘landmark’ trial showing mRNA therapy significantly cuts odds of recurrent skin cancer
The combined drug works by nudging the body’s own immune system to make proteins that attack and destroy melanoma cells
5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on www.scientificamerican.com — the content belongs to Scientific American.
